Brief: Actinium Announces Clinical Trial to Study Targeted Radiotherapy Conditioning with FDA Approved CAR T-Cell Therapy
26/03/2024 11:22
March 26 (Reuters) - Actinium Pharmaceuticals Inc
ATNM.A :
* ACTINIUM ANNOUNCES CLINICAL TRIAL TO STUDY IOMAB-ACT
TARGETED
RADIOTHERAPY CONDITIONING WITH LEADING FDA APPROVED COMMERCIAL
CAR T-CELL THERAPY
Source text for Eikon: ID:nPn27SN5Xa
Further company coverage: ATNM.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Actinium Pharmaceuticals
See all newsBrief: Actinium Pharmaceuticals - Receives Two Canadian Patent Allowances For Actimab-A And Iomab-Act Programs
Brief: ctinium’s Atnm-400 Shows Strong Efficacy in TNBC, Beats Therapy Resistance at SABCS
Brief: Actinium Pharmaceuticals Says ATNM-400 Shows Superior Efficacy To Xtandi In Prostate Cancer
Brief: Actinium Pharmaceuticals Announces ATNM-400 A Novel Non-PSMA Targeting First In Class Prostate Cancer Radiotherapy Leveraging Actinium-225
Brief: Actinium Pharmaceuticals Announces Supply Agreement With Eckert & Ziegler For AC-225 Radioisotope To Support Comprehensive Development Activities